Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and their Clinical Implications

Title:Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and their Clinical Implications

Volume: 19 Issue: 19

Author(s): Yoshiro Sohma, Ying-Chun Yu and Tzyh-Chang Hwang

Affiliation:

Keywords: Additive effect, synergistic effect, G551D.

Abstract: Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D.

Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators.

In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.

Cite this article as:

Sohma Yoshiro, Yu Ying-Chun and Hwang Tzyh-Chang, Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and their Clinical Implications, Current Pharmaceutical Design 2013; 19 (19) . https://dx.doi.org/10.2174/13816128113199990320